In his opening remarks, Mr. Yves Aguilos, GPCCI Head of Government Affairs and Data Protection Officer, emphasized the importance of engaging on customs regulations, enforcement priorities, and practical trade compliance challenges. He highlighted the BOC’s critical role in business continuity amid global trade complexities and supply chain disruptions, and underscored the Dialogue Series as a venue for aligning public- and private-sector perspectives on regulatory reform.
Assistant Commissioner Vincent Phillip C. Maronilla provided updates on the BOC’s digitalization efforts, governance initiatives, and measures to strengthen accountability. He outlined reforms aimed at improving trade facilitation, reducing disputes, and enhancing service delivery. Key topics included crisis response measures, the rollout of the National Single Window–Interoperability Framework and Platform (NSW-ITFP), tariff classification and valuation issues, inter-agency digitalization, and the implementation of Customs Administrative Order (CAO) No. 01-2026.
The Q&A session, moderated by Mr. Stefan Schmitz, Former GPCCI Senior Vice President and President of FLS Group, raised key concerns from the business community, including:
- Crisis response and customs facilitation amid global disruptions
- NSW-ITFP implementation timelines and support mechanisms
- Tariff classification and valuation dispute resolution
- Digital transformation and BOC–BIR interoperability
- Implementation of CAO No. 01-2026 on importer accreditation
Closing the session, PAC Vice Chairperson Ms. Marie Antoniette Mariano thanked the BOC and participants, emphasizing the importance of sustained collaboration in building a transparent, predictable, and efficient trade environment.
The session highlighted the value of continued public-private dialogue in addressing operational challenges and advancing meaningful regulatory reforms. GPCCI reaffirmed its commitment to the IMPACT Dialogue Series, with upcoming engagements planned with agencies such as the Securities and Exchange Commission (SEC) and the Food and Drug Administration (FDA) to support trade facilitation, ease of doing business, and economic resilience.
